|
Becaplermin
resources
DRUG INFO
Becaplermin
Drug Name:
Becaplermin
|
|
|
Indication: For topical treatment of skin ulcers (from diabetes)
Pharmacology: Used for the topical treatment of skin ulcers, Regranex has a biological activity similar to that of endogenous platelet-derived growth factor, which includes promoting the chemotactic recruitment and proliferation of cells involved in wound repair and enhancing the formation of granulation tissue.
Mechanism Of Action: Binds to the beta platelet-derived growth factor (PDGF) receptor, a tyrosine kinase receptor. PDGF is known to exist as a dimer, and activates its signaling pathway by a ligand induced receptor dimerization and autophosphorylation. PDGF receptors also contain many auto-phosphorylation sites, which serve to mediate binding of SH2 sites and subsequently signal corresponding pathways. There are five different isoforms of PDGF that activate through two different receptors (alpha and beta).
Drug Category: Anti-Ulcer Agents; Topical; cell stimulants and proliferants (84:16.00)
Brand Names/Synonyms: Platelet-derived growth factor B chain precursor;PDGF B-chain;Platelet-derived growth factor beta polypeptide;PDGF-2;c-sis;Becaplermin; Regranex (OMJ Pharmaceuticals; Inc; Chiron Corp.)
Dosage Forms: GEL
Absorption: Not Available
Interactions: Not Available
Chemical IUPAC Name: Human platelet derived growth factor
Chemical Formula: C532H892N162O153S9
Half Life: Not Available
Drug Type: Approved Drug
# Accession No: BIOD00053
CAS Registry Number: 165101-51-9
| | |
